1) While the manuscript is precisely and accurately written, some expressions are awkward. The English language needs editing.
2) The aim of this project is obscure. It is unclear why alogliptin was chosen out of many DPP-4 inhibitors. Is it the sponsor's intention or investigators own interests? Preliminary studies have implicated that, in comparison to other DPP-4 inhibitors, alogliptin appears to possess a favorable profile in ameliorating atherogenic lipids or antiatherogenic molecules. This can be a good background. These studies may be cited.
3) Although it is stated that this study is conducted as an investigator-initiated research and that all relevant procedures will be undertaken in a funding sponsor-independent manner, this needs to be verified in an object way. If the study is to be performed in such a way, the funding should be from somewhere else (e.g. public source, not from pharmaceutical companies). Otherwise, certain degrees of bias cannot be avoided. For example, the sponsor intended to increase the sales of alogliptin by funding this study. This is because some clinical studies from Japan were not performed properly in the past (e.g. Jikei Heart Study, Kyoto Heart Study). These studies were supposed to be a physician-initiated, sponsor-independent manner. However, in reality, this was not undertaken as such.
4) This is a rather small protocol paper. However, there are too many authors. Those who have significantly and truly contributed should be the authors 5) All authors have conflicts of interest with the sponsor. Certain degrees of neutrality need to be guaranteed. For example, at least one researcher without any connection with the sponsor should be the author.
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GENERAL COMMENTS
Statistical analysis: 1. The authors justify sample size for some of their primary outcomes but not all of them 2. The authors need to provide data about how they plan to analyse the data, how they will handle missing data and how they will account for baseline differences between groups Outcomes: 1. Is a 3-year follow up is enough for the cancer outcome? 2. What are the methods and criteria used to diagnose microvascular complications Methods: 1. How are patients going to be assigned to treatment arms? 2. Why Alogliptin rather than other DPP-4 inhibitors or all DPP-4 inhibitors? 3. What about women who become pregnant during the study, will they be excluded? 4. The authors describe the study as "randomised observational" in the summary, what does that mean? There is no mention on randomisation anywhere in the article and if it is randomised then the study is interventional Funding: 1. What is the role of funders in design and analysis?
VERSION 1 -AUTHOR RESPONSE
Responses to Reviewer 1's comments 1) While the manuscript is precisely and accurately written, some expressions are awkward. The English language needs editing.
A: We had a native writer's check and incorporated his comments in the revised manuscript.
2) The aim of this project is obscure. It is unclear why alogliptin was chosen out of many DPP-4 inhibitors. Is it the sponsor's intention or investigators own interests? Preliminary studies have implicated that, in comparison to other DPP-4 inhibitors, alogliptin appears to possess a favorable profile in ameliorating atherogenic lipids or anti-atherogenic molecules. This can be a good background. These studies may be cited.
A: Thank you so much for kind advice. We changed the original text (INTRODUCTION; p.9, first paragraph; line 4) as: "Since DPP-4 inhibitors, particularly alogliptin (Nesina®), have recently been implicated in a beneficial, anti-atherogenic mechanism to reduce a risk of cardiovascular events15-17, alogliptin was chosen as a representative DPP-4 inhibitor throughout J-BRAND Registry study. The drug will be administered to the planned 10,000 patients, as per its package insert (25 mg once daily, except for patients associated with moderate-to-severe kidney malfunction, who are to receive either 6.25 mg or 12.5 mg daily at physician's discretion), while OHAs other than DPP-4 inhibitors will be used in another 10,000 patients for comparison (see Methods and analysis)."
The following literatures are newly added due to this change. Literatures are renumbered accordingly hereafter in the manuscript (p.32; References section). 3) Although it is stated that this study is conducted as an investigator-initiated research and that all relevant procedures will be undertaken in a funding sponsor-independent manner, this needs to be verified in an object way. If the study is to be performed in such a way, the funding should be from somewhere else (e.g. public source, not from pharmaceutical companies). Otherwise, certain degrees of bias cannot be avoided. For example, the sponsor intended to increase the sales of alogliptin by funding this study. This is because some clinical studies from Japan were not performed properly in the past (e.g. Jikei Heart Study, Kyoto Heart Study). These studies were supposed to be a physicianinitiated, sponsor-independent manner. However, in reality, this was not undertaken as such.
A: The authors understand quite well the reviewer's point. That is why this study has been designed as a strictly physician-initiated, sponsor-independent one, in which the Sponsor (Takeda Ph.) will provide funding only and is supposed not to be involved in any study-related activities/procedures including study design, patient treatment, data management, statistical analysis, publication, investigator meeting, etc. Takeda has agreed with all the participating physicians with respect to this manner and expressed their intention to strictly follow the agreement. The proposed study will thus be conducted only by study physicians with assistance from Clinical Research Organizations. We physicians completely understand the recent, serious situation surrounding the science world of Japan. But, we also understand that the situation would be a good reason why we will and have to comply with the rule (with a strong will) agreed between Physicians, Takeda and CROs to avoid any bias which may arise during the study. Takeda is a leading pharmaceutical company in Japan and understands that the Japanese science should be jeopardized and lose its credibility and reputation across the world, if Takeda misleads the study.
The point of this explanation was incorporated in the last paragraph of Competing interests section (p.29; last paragraph) of the revised manuscript.
4) This is a rather small protocol paper. However, there are too many authors. Those who have significantly and truly contributed should be the authors.
A: As summarized in the contribution list (please see the answer to Editors Comment), each author has made a significant contribution to publish this article. We therefore consider it will be appropriate to keep all the authors as appearing in the manuscript.
5) All authors have conflicts of interest with the sponsor. Certain degrees of neutrality need to be guaranteed. For example, at least one researcher without any connection with the sponsor should be the author.
A: We understand the strong concern of the reviewer about any bias potentially arising in this study. However, we believe the answer to comment 3) of the same reviewer will nullify such concern. Physicians and CROs will take any actions in order to avoid any bias potentially evoked by the sponsor, and Takeda will never take any actions that may potentially cause any bias during the study.
Responses to Reviewer 2's comments
Statistical analysis: 1. The authors justify sample size for some of their primary outcomes but not all of them.
A: The reviewer's comment is right. However, we have little information about other primary outcomes. We thus believe that the presented justification is valid at present for the planned sample size.
2. The authors need to provide data about how they plan to analyse the data, how they will handle missing data and how they will account for baseline differences between groups.
A: Safety is the primary outcome in this study. Hypoglycemia, pancreatitis, skin disorders, infections and cancer will be of particular interest. These outcomes will be analyzed primarily by Kaplan-Meier method for estimation of cumulative incidence and by log-rank test for between-group comparison. If necessary, multivariate methods including Cox regression may be used to adjust baseline differences. Efficacy is the secondary outcome. A1C, fasting blood glucose, fasting insulin, and urinary albumin will be measured at each visit and the change from baseline (at registration) will be compared between groups by two-sided t test. Missing data will be imputed by Last-Observation-Carried Forward method. If necessary, multivariate methods including ANCOVA may be used for adjustment of baseline differences. The effect of OHA(s) on the new onset of microangiopathy and its progression will be assessed by Kaplan-Meier method and log-rank test, as performed in hypoglycemia assessment.
This explanation was incorporated in Statistical and analytical plans section (p.23; second paragraph) of the revised manuscript.
Outcomes: 1. Is a 3-year follow up is enough for the cancer outcome?
A: We think the reviewer's comment is quite valid. However, the 3-year period was determined, in relation to the study aspect including (i) safety event detectability (99% or higher probability to detect at least one subject who develops one safety event with its incidence rate of <0.05%) and an assumed rate of dropouts which lead to the planned population size of 10,000 each of the two treatment groups, and (ii) statistical power of >90% (please, see Rationale for planned sample size section; p.23 of the revised manuscript). We will thus be able to detect a rare event during 3-year study period. Since recent reports suggest the patients with diabetes mellitus to be associated with an increased risk for various types of cancer, we may expect to detect cancerous events during the 3-year period.
2. What are the methods and criteria used to diagnose microvascular complications.
A: The diagnosis of diabetic retinopathy is made by a funduscopic method based on Davis classification as simple retinopathy (SDR) or more advanced. The diagnosis of diabetic neuropathy is made based on classification proposed by Toronto DPN Expert Group (Diabetes Care 33: 2285-2293, 2010) as Probable DPN or higher. Diabetic nephropathy is based on urinary albumin/creatinine ratio as 30 mg/g Cr or higher.
These criteria were included in Microangiopathy and other measurements section (p.18; first paragraph) of the revised manuscript. The article of Toronto Expert Group was newly added in References section as No. 18 (p.32 of the revised manuscript).
Methods: 1. How are patients going to be assigned to treatment arms?
A: The investigator will give an explanation about the study to each patient using a specific Informed Consent Form. It should be noted that this study will be conducted in an open state in daily clinical practice, and hence no randomization occurs; each patient may arbitrarily choose his/her assignment to either Group A or Group B when he or she provides a written consent.
To make this clearer, we modified the manuscript in INTRODUCTION section (p.9; first paragraph) as: "We therefore have scheduled a prospective, observational study (Japan-Based clinical ReseArch Network for Diabetes Registry: J-BRAND Registry) of actual cases with long term experience in daily clinical practice: this type of research may be as useful for practicing the EBM as is an interventional, randomized study.
We also added one sentence in Overall study design section (p.12; first paragraph, line 4) as: "Each participating patient will choose either treatment group according to his or her free will."
Why Alogliptin rather than other DPP-4 inhibitors or all DPP-4 inhibitors?
A: DPP-4 inhibitors, particularly alogliptin, are of recent interest because of their potential anti-atherogenic effects (please refer for example to a literature Reference 15: Shailendra Kapoor; Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 121-123). This is why we chose alogliptin as a representative DPP-4 inhibitor (also, see the answer to Reviewer 1's comment 2).
This explanation was included in INTRODUCTION section (p.9, first paragraph; line 4), as "Since DPP-4 inhibitors, particularly alogliptin (Nesina®), have recently been implicated in ---------", with 3 related articles included in References (p.32; 3. What about women who become pregnant during the study, will they be excluded?
A: Exclusion criteria (Table 1) states pregnant or lactating women will be excluded from the study. Women are to terminate the study when found pregnant. This is stated in Subject eligibility section (p.13, last paragraph)
4. The authors describe the study as "randomised observational" in the summary, what does that mean? There is no mention on randomisation anywhere in the article and if it is randomised then the study is interventional A: We sincerely apologize for our fault. We change a word "randomized" to "non-randomized" in Article Summary. The proposed study is indeed a non-randomized, observational study conducted in daily clinical practice.
Funding: 1. What is the role of funders in design and analysis?
A: Takeda Ph. Co. Ltd. is the funder. As stated in the manuscript (Competing interests section; p.29-30 of the revised manuscript), this study will be conducted in a strictly investigator-initiated and sponsor-independent manner. While CROs provide assistance in administrative management, data management, statistical analysis and publication, the assistance will be performed in a manner completely independent from Takeda. Takeda will thus never be involved in any scientific activities such as study design, data management, statistical analysis, investigator meeting, publication including presentation at a scientific conference, and so forth, with no contact to physicians or CROs. Consequently, Takeda will contribute to the study conduct only as a financial supporter.
This consideration was included in Competing interests section of the manuscript (p.29-30).
Other specific revisions
As advised, the corrected "Article Summary" was placed just after "Abstract". For reviewers convenience, we made some comments in the revised-tracked manuscript as appropriate.
